


Claims:

1. A compound of Formula I, or a salt, solvate, or hydrate thereof:



wherein

- 5 R^1 and R^2 are each independently selected from H, OH, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylCO₂, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), C₁₋₆alkyl(C=O)NH, C₁₋₆alkyl(C=O)N(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, O-Si(C₁₋₆alkyl)(C₁₋₆alkyl)(C₁₋₆alkyl), NO₂, CF₃, OCF₃ and halo, or R^1 and R^2 together represent O-C₁₋₆alkyl-O, thereby forming a ring;
- 10 R^3 is selected from H, OH, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylCO₂, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), C₁₋₆alkyl(C=O)NH, C₁₋₆alkyl(C=O)N(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, O-Si(C₁₋₆alkyl)(C₁₋₆alkyl)(C₁₋₆alkyl), NO₂, halo and CH₂-S-(CH₂)_n Ar;
- 15 R^4 is selected from C(X)R⁵, SO₃Ar, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), P(O)(OH)₂, P(O)(OC₁₋₆alkyl)₂, and C(NH₂)=C(CN)₂;
- X is selected from O, S, NH and N-C₁₋₆alkyl;
- 16 R^5 is selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH, (CH₂)_pOC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkoxy, NHNH₂, NHC(O)NH₂, NHC(O)C₁₋₆alkoxy, N-morpholino and N-pyrrolidino; and
- 20 Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo;
- 21 n is 0 to 4; and
- 25 p is 1-4.

2. The compound according to claim 1, wherein R^1 and R^2 are each independently selected from H, OH, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylCO₂, NH₂, NH-

C₁₋₄alkyl, C₁₋₄alkyl(C=O)NH, C₁₋₄alkyl(C=O)N(C₁₋₄alkyl), SH, S-C₁₋₄alkyl, O-Si(C₁₋₄alkyl)(C₁₋₄alkyl)(C₁₋₄alkyl), NO₂, CF₃, OCF₃ and halo, or R¹ and R² together represent O-C₁₋₆alkyl-O, thereby forming a ring.

3. The compound according to claim 2, wherein R¹ and R² are each 5 independently selected from the group consisting H, OH, OCH₃, CH₃CO₂, O-Si(CH₃)₂(^tBu), S-Me, SH, CH₃CONH, CH₃CONCH₃, and NO₂.

4. The compound according to claim 3, wherein R¹ and R² are both OH or R¹ and R² are both OCH₃.

5. The compound according to claim 4, wherein R¹ is OCH₃ and R² is 10 OH.

6. The compound according to claim 1, wherein R³ is selected from H, OH, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylCO₂, NH₂, NH-C₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), C₁₋₄alkyl(C=O)NH, C₁₋₄alkyl(C=O)N(C₁₋₄alkyl), SH, S-C₁₋₄alkyl, NO₂ and halo.

15 7. The compound according to claim 6, wherein R³ is selected from selected from H, OH, OCH₃, CH₃CO₂, SH, SMe, NO₂, CH₃CONH, CH₃CONCH₃, and halo.

8. The compound according to claim 1, wherein R¹, R², and R³ are each independently selected from H, C₁₋₄alkylCO₂, C₁₋₆alkyl(C=O)NH, and C₁₋₆alkyl(C=O)N(C₁₋₆alkyl), provided that at least one of R¹, R², and R³ is not hydrogen. 20

9. The compound according to claim 1, wherein R⁴ is selected from selected from C(X)R⁵ and C(NH₂)=C(CN)₂.

10. The compound according to claim 9, wherein R⁴ is C(X)R⁵.

11. The compound according to claim 10, wherein X is selected from selected from O and S.

12. The compound according to claim 10, wherein R⁵ is selected from selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH and C₁₋₄alkoxy.

5 13. The compound according to claim 12, wherein p is 1-3.

14. The compound according to claim 13, wherein R⁵ is selected from selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH and OCH₃.

15. The compound according to claim 14, wherein p is 1-2.


16. The compound according to claim 1, wherein Ar is an unsubstituted phenyl group or a phenyl group substituted with 1-4 substituents optionally selected from selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo.


17. The compound according to claim 14, wherein Ar is an unsubstituted phenyl group or a phenyl group substituted with 1-4 substituents optionally selected from selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo.


18. The compound according to any of claims 16 and 17, wherein Ar is an unsubstituted phenyl group or phenyl group substituted with 1-2 substituents optionally selected from selected from OH, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, NH-C₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), SH, S-C₁₋₄alkyl, NO₂, CF₃, OCF₃ and halo.


19. The compound according to claim 18, wherein Ar is an unsubstituted phenyl group or phenyl group substituted with 1-2 substituents optionally selected from OH, OCH₃, NH₂, NHCH₃, N(CH₃)₂, SH, SCH₃, CF₃, OCF₃ and halo.


20. A compound selected from:

























5







10
















5











5





























;




;




;




;




;




;




;



;





21. A composition comprising a compound according to any one of
 10 claims 1 to 20 in admixture with a pharmaceutically acceptable diluent or carrier.

22. A use of a compound capable of modulating cell proliferation according to any one of claims 1 to 20 to prepare a medicament to modulate cell proliferation.

23. A use of a compound capable of inhibiting cell proliferation according to any one of claims 1 to 20 to inhibit cell proliferation.

24. A use of a compound capable of inhibiting cancer cell proliferation according to any one of claims 1 to 20 to inhibit cancer cell proliferation.

25. A use of a compound according to any one of claims 1 to 20 to treat cancer.

10 26. A use according to claim 24 or 25 wherein said cancer is a hematopoietic cell cancer.

27. A use according to claim 24 or 25 wherein said cancer is a leukemia, a lymphoma, a myeloma or a carcinoma.

15 28. A use according to claim 27 wherein said leukemia is acute lymphoblastic leukemia, Philadelphia+ leukemia, Philadelphia- leukemia, acute myelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or juvenile myelomonocyte leukemia.

29. A use according to claim 27 wherein said leukemia is acute lymphoblastic leukemia.

20 30. A method of modulating cell proliferation comprising administering an effective amount of a compound capable of modulating cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

31. A method of inhibiting cell proliferation comprising administering an effective amount of a compound capable of inhibiting cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

5 32. A method of inhibiting cancer cell proliferation comprising administering an effective amount of a compound capable of inhibiting cancer cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

10 33. A method of treating cancer comprising administering an effective amount of a compound capable of inhibiting cancer cell proliferation according to any one of claims 1 to 20 or a composition according to claim 21 to a cell or animal in need thereof.

34. A method according to claim 32 or 33 wherein said cancer is a hematopoietic cell cancer.

15 35. A method according to claim 32 or 33 wherein said cancer is a leukemia, a lymphoma, a myeloma or a carcinoma.

36. A method according to claim 35 wherein said leukemia is acute lymphoblastic leukemia, aggressive Philadelphia+ leukemia, acute myelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or juvenile 20 myelomonocyte leukemia,

37. A method according to claim 35 wherein said leukemia is acute lymphoblastic leukemia.